Over the previous few years, Eli Lilly(NYSE: LLY) has delivered sturdy returns, largely because of its medical progress, significantly in a single key space: weight administration. The corporate’s efforts on this area of interest are already paying wealthy dividends.
Nevertheless, the pharmaceutical chief is not stopping but. It already leads this space, and its latest developments counsel it may depart its rivals within the mud. Can any firm catch as much as Eli Lilly within the weight reduction drug battle?
It is value noting that, though many firms are looking for to enter this market, just one poses a severe risk to Eli Lilly, and that is Novo Nordisk(NYSE: NVO). The Denmark-based pharmaceutical large markets Wegovy, an anti-obesity drugs that generates billions in annual gross sales.
Moreover, Novo Nordisk is anticipating vital label expansions. It lately requested approval from the U.S. Meals and Drug Administration for the next dose of semaglutide (the lively ingredient in Wegovy).
Picture supply: Getty Pictures.
The model of Wegovy with the upper dose proved more practical in serving to sufferers shed pounds in medical trials. There’s additionally an oral formulation of semaglutide awaiting regulatory approval within the U.S.
However Eli Lilly’s Zepbound is greatest in school. Zepbound induced larger common weight reduction than Wegovy in a head-to-head examine. And thru the primary 9 months of 2025, Zepbound generated $9.3 billion in income. Wegovy generated roughly $9 billion — regardless of having been authorized within the U.S. greater than two years earlier than its competitor.
May Novo Nordisk’s pipeline candidates assist it catch up? Along with the anticipated label expansions, the corporate is creating merchandise reminiscent of Amycretin, which has each oral and subcutaneous formulations in part 3 research.
Even their pipelines, although, Eli Lilly is the winner. The corporate posted sturdy part 3 knowledge for orforglipron, an oral weight reduction drugs, this yr. It ought to earn approval for that candidate someday in 2026. Extra lately, Eli Lilly delivered one more vital win, this time with retatrutide, an investigational weight reduction remedy that delivered a imply weight lack of 28.7% on the highest dose in a part 3 examine.
Even Novo Nordisk’s CagriSema, which posted 22.7% imply weight reduction — and is now underneath regulatory evaluate for approval within the U.S. — pales compared. So Eli Lilly is clearly forward of its greatest rival right here.
Different firms are too far behind to hope to catch Eli Lilly. Positive, there are attention-grabbing pipeline candidates on the market, however nobody appears to have a extra spectacular lineup.
What’s extra, Eli Lilly is protecting as many bases as doable. Zepbound is run subcutaneously. Some thought they might be capable to get a leg up on Eli Lilly with an efficient oral weight reduction drugs, however then orfoglipron carried out very effectively in medical trials. The corporate can be engaged on anti-obesity therapies that concentrate on hormones apart from GLP-1, in addition to some that may be administered much less continuously.
Eli Lilly ought to stay the highest participant on this space for some time.
So, what does that every one imply for the inventory? The corporate is already posting sturdy gross sales and earnings progress because of its success. Its third-quarter income jumped 54% yr over yr to $17.6 billion, whereas its adjusted web earnings got here in at $6.3 billion, considerably increased than the $1.1 billion reported in the identical interval final yr. With new launches on this space, Eli Lilly ought to keep wonderful top- and bottom-line progress no less than via the top of the last decade. Some may argue that its success is already baked into its inventory worth.
Nevertheless, there’s nonetheless appreciable upside left for the corporate, and it might proceed to ship sturdy returns. Eli Lilly’s worth/earnings-to-growth ratio of 1 is inside the “pretty valued” vary.
Along with its dominance in weight reduction, there are a number of compelling causes to contemplate the inventory. Certainly one of them is the dividend. Even with an unimpressive ahead yield of 0.6% (which is hardly shocking contemplating its shares have skyrocketed over the previous 5 years), Eli Lilly routinely will increase its payouts, which have greater than doubled since 2020.
Eli Lilly is a prime inventory for progress and dividends traders to purchase right this moment and maintain on to for some time.
Before you purchase inventory in Eli Lilly, think about this:
The Motley Idiot Inventory Advisor analyst group simply recognized what they imagine are the 10 greatest shares for traders to purchase now… and Eli Lilly wasn’t one in every of them. The ten shares that made the minimize may produce monster returns within the coming years.
Contemplate when Netflix made this listing on December 17, 2004… if you happen to invested $1,000 on the time of our suggestion, you’d have $504,994!* Or when Nvidia made this listing on April 15, 2005… if you happen to invested $1,000 on the time of our suggestion, you’d have $1,156,218!*
Now, it’s value noting Inventory Advisor’s whole common return is 986% — a market-crushing outperformance in comparison with 196% for the S&P 500. Do not miss the most recent prime 10 listing, obtainable with Inventory Advisor, and be part of an investing neighborhood constructed by particular person traders for particular person traders.
